<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253940</url>
  </required_header>
  <id_info>
    <org_study_id>1188.33</org_study_id>
    <nct_id>NCT02253940</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Crossover Relative BA Study of Pharmacokinetics and Safety of New SDS-containing Tablet and Capsule Formulations of BILR 355 Compared to the Current Formulation (50 mg Tablet), After Single Dose Oral Administration of BILR 355 Plus Low Dose Ritonavir in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the single dose, relative BA of new SDS-containing formulations of BILR
      355 (150 mg and 200 mg capsules and 150 mg tablet), compared to the current SDS tablet
      formulation (50 mg tablet)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-inf (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of analyte in plasma)</measure>
    <time_frame>up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte in plasma)</measure>
    <time_frame>up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte in plasma)</measure>
    <time_frame>up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance of the analyte in the plasma after extravascular administration)</measure>
    <time_frame>up to 96 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 12 days following last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal changes in laboratory parameters</measure>
    <time_frame>up to 48 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose Group 1 - low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequences ABC / CAB / BCA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 2 - high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment sequences DE / ED</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILR 355 - Treatment A (current tablet formulation)</intervention_name>
    <arm_group_label>Dose Group 1 - low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILR 355 - Treatment B (new tablet formulation)</intervention_name>
    <arm_group_label>Dose Group 1 - low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILR 355 - Treatment C (new capsule formulation)</intervention_name>
    <arm_group_label>Dose Group 1 - low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILR 355 - Treatment D (current tablet formulation)</intervention_name>
    <arm_group_label>Dose Group 2 - high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BILR 355 - Treatment E (new capsule formulation)</intervention_name>
    <arm_group_label>Dose Group 2 - high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>Dose Group 1 - low dose</arm_group_label>
    <arm_group_label>Dose Group 2 - high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy HIV negative adult male volunteers

          2. Age ≥18 and ≤60 years

          3. BMI ≥18.5 and BMI ≤29.9 kg/m2

          4. Ability to give signed and dated written informed consent prior to admission to the
             study in accordance with Good Clinical Practice (GCP) and the local regulations

        Exclusion Criteria:

          1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          2. Surgery of gastrointestinal tract (except appendectomy)

          3. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          4. History of relevant orthostatic hypotension, fainting spells or blackouts

          5. Chronic or relevant acute infections

          6. History of allergy/hypersensitivity (including drug allergy) which was deemed relevant
             to the trial as judged by the investigator

          7. Intake of drugs with a long half-life (&gt;24 hours) within at least one month prior to
             study drug administration and during the trial

          8. Use of drugs within 10 days prior to administration or during the trial which might
             reasonably influence the results of the trial

          9. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         10. Current smoker

         11. Alcohol abuse (more than 60 g/day)

         12. Drug abuse (positive urine test for illicit prescription or non-prescription drugs or
             drugs of abuse)

         13. Blood donation (more than 100 mL within four weeks prior to study drug administration
             or during the trial)

         14. Excessive physical activities (within one week prior to study drug administration or
             during the trial)

         15. Any laboratory value outside the reference range that was of clinical relevance at
             screening, according to the judgment of the investigator

         16. Inability to comply with dietary regimen required by the protocol

         17. Infected with hepatitis B or hepatitis C viruses (defined as either being hepatitis B
             surface antigen, or hepatitis C antibody positive)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 30, 2014</last_update_submitted>
  <last_update_submitted_qc>September 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

